Can the clinical performance of oral Somaupeptide 3 be shaken?

Drug source analysisAlthough this year's ASCO is considered to be a small year, but ada than the new mechanism is much more, the main reason is that diabetes is a lot of drugs, two is to show the advantages of investment too muchSafe sugar is not enough, and it's hard to get a boost from weight, cardiovascular, and even other benefitsI took a look at the main developments in ADA and there wasn't anything new that was too excitingCD3 antibody teplizumab in high-risk groups delayed the onset of type 1 diabetes by 2 years is an unexpected development, but also raised a lot of questions, GLP field competition is one of the main concernsGLP is a relatively old target, the first drug Byetta was launched in 2005, and the group fights of the past 15 years have focused on optimizing the two main efficacy sprees of sugar reduction, weight loss and ease of useByetta had to be injected twice a day, and then Novo nor Nordisk developed a one-day injection of liraglutide and got a double label to reduce sugar and lose weight, becoming the first drug in history to be a needle weight loss drugLater AZN, Lilly, Glaxo developed a weekly Bydureon, Trulicity, and Tanzeum, especially Trulicity, which was ferocious and quickly encroached on Victoza's turfTanzeum saw the situation go bad and withdraw earlySoma, though not the most agile but now looking at the effect sbetter, beat Trulicity in a head-to-head trial the year beforeOzempic reduced the CV risk by 26% in the CV trial and the oral version of Soma by 21%, which is better than the 12% that just announced TrucityOral polypeptide drugs have been a technical barrier, and Soma is expected to become the first oral GLP drug to increase local pH using an accessory called SNAC to avoid degradationone of Lilly's main coping strategies is its GIP/GLP double-excitement tirzepatideBoth GIP and GLP are hormones that the gastrointestinal apprehwho promotes insulin secretion, known as gastrointestinal secretion of insulin (Incretin)However, diabetics develop resistance to GIP, so single GIP agonist sugar reduction effect is not very goodLast year tirzepatide in a phase II clinical lysing and weight loss of high activity, high-dose group (15 mg) HbA1C decreased by 2.4%, weight loss of 11.3 kg, but the side effects of this dose is very large, 12 weeks of withdrawal rate of up to 32%But the effect of this dose is too tempting, so Lilly hopes to reduce side effects by titration (increasing the dose gradually from a low dose) The second phase of the clinical, announced yesterday, used two different rhythms to increase the dose, reducing the withdrawal rate to less than 4% Unfortunately, the effect also seemed to decline, with HbA1c dropping at about 2% and weight dropping at about 5.5 kg It remains to be seen whether Tirzepatide's Phase III clinical will use another titration plan to find a better window into the efficacy/side effects Of course Lilly is also developing a slightly lower dose (10 mg), which would probably be the most commercially viable dose of course Soma also had gastrointestinal problems, with a 9% exit rate for the PIONEER7 trial Soma oral bioavailability is very low, estimated at around 1-2%, so the cost is higher than the injection version In addition, Soma needs to take on an empty stomach for 6 hours, after taking the drug also empty stomach for half an hour, although stronger than injection is also an inconvenient factor Even with these headwinds, it is now difficult to shake the leadership of oral soma by other GLP drugs As for the same glP why Soma finally won all-round, it may be that Novo nor Nord is more patient, or it may be luck The introduction of GIP function may theoretically improve the efficacy, but most drugs not only look at the efficacy, but also look at the treatment window Swapping side effects for treatment is only possible for the deadliest diseases such as advanced tumors, and diseases such as diabetes, which has more than a dozen types of drugs, require much higher safety original title: Originals .